EUVIMEDScopri EUVIMED
Open access · CC BY 4.0

Topical Photodynamic Therapy in a Medical Centre: The Scottish Dermatology Experience

Chayada Chaiyabutr iD, Robert Dawe iD, Andrea Lesar, Sally H Ibbotson iD

Photodermatology, Photoimmunology & Photomedicine · 2025

DOI: 10.1111/phpp.70010 ↗

At a glance

Journal article in Photodermatology, Photoimmunology & Photomedicine, 2025. Written by Chayada Chaiyabutr and 3 co-authors. Institution: Department of Dermatology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand. Major MEDLINE topics: Photochemotherapy, Skin Neoplasms, Basal Cell Carcinoma, Keratosis, Actinic. 25 references. The full text is freely available (open access, CC BY 4.0).

AbstractSubjectsDati bibliograficiCiteRelated studies

Abstract (original language)

Background

Topical photodynamic therapy (PDT) is widely used in dermatology for treating superficial non‐melanoma skin cancer (NMSC) and dysplasia. This study aims to assess real‐world outcomes of PDT in a Scottish dermatology service.

Methods

We retrospectively reviewed patients with superficial NMSC and dysplasia who underwent conventional and daylight PDT at the Photobiology Unit, Dundee, Scotland.

Results

A total of 705 patients with 2108 NMSC and precancerous skin lesions underwent conventional PDT. Clearance at 12 months was achieved in 53.4% of actinic keratoses (AK), 71.3% of Bowenoid AK, 86.4% of Bowen's disease (BD), 89.0% of superficial basal cell carcinoma (BCC), and 89.7% of nodular BCC. On multivariate analysis, small lesion size and thin histological tumour thickness of superficial BCC were features, which were associated with likelihood of achieving clearance after PDT. Female sex, head/neck sites, larger lesion size, strong pre‐treatment fluorescence intensity, fluorescence specificity, prominent treatment‐induced erythema and an urticarial reaction were associated with moderate to severe pain during PDT. Daylight PDT for 77 AK patients (158 treatments) showed excellent or good outcomes in 63.3% of lesions. Higher visible light exposure is correlated with better treatment outcomes.

Conclusions

In real‐life settings, whilst the PDT response rates of BD and selected BCC are high and consistent with clinical trial outcomes, the efficacy rates for AK appear lower than expected. This emphasizes the need for realistic expectations in chronic disease management. Through review over a prolonged period, factors associated with PDT tolerability and outcomes were identified, allowing predictive utilisation for optimizing patient‐centred PDT regimens.

Subjects

MeSH terms (MEDLINE)

PhotochemotherapySkin NeoplasmsBasal Cell CarcinomaKeratosis, ActinicBowen's DiseasePhotosensitizing AgentsHumansFemaleMaleAgedRetrospective StudiesMiddle AgedScotlandAged, 80 and overAdult

Author keywords

Bowen's diseaseactinic keratosesbasal cell carcinomadaylightphotodynamic therapy

Substances

Photosensitizing Agents

Authors and institutions

  • Department of Dermatology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
  • Scottish Photodynamic Therapy Centre, Photobiology Unit, University of Dundee & NHS Tayside, Ninewells Hospital & Medical School, Dundee, UK.

ORCID profiles: Chayada Chaiyabutr, Robert Dawe, Sally H Ibbotson

Cite

APA

Chaiyabutr, C., Dawe, R., Lesar, A., & Ibbotson, S. H. (2025). Topical Photodynamic Therapy in a Medical Centre: The Scottish Dermatology Experience. Photodermatology, Photoimmunology & Photomedicine. https://doi.org/10.1111/phpp.70010

Vancouver

Chaiyabutr C, Dawe R, Lesar A, Ibbotson SH. Topical Photodynamic Therapy in a Medical Centre: The Scottish Dermatology Experience. Photodermatology, Photoimmunology & Photomedicine. 2025. doi:10.1111/phpp.70010

BibTeX
@article{Chaiyabutr2025,
  author = {Chaiyabutr, Chayada and Dawe, Robert and Lesar, Andrea and Ibbotson, Sally H},
  title = {Topical Photodynamic Therapy in a Medical Centre: The Scottish Dermatology Experience},
  journal = {Photodermatology, Photoimmunology & Photomedicine},
  year = {2025},
  doi = {10.1111/phpp.70010}
}
Start for free →